医学
甘油三酯
安慰剂
药品
内科学
非诺贝特
糖尿病
胆固醇
内分泌学
2型糖尿病
药理学
替代医学
病理
摘要
Pemafibrate is a selective peroxisome proliferator–activated receptor α modulator that has putative greater triglyceride-lowering and high-density lipoprotein (HDL) cholesterol–raising properties than other fibrates.1 Now in the Journal, Das Pradhan et al.2 describe the results of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) trial. In this trial, 10,497 patients with type 2 diabetes, a triglyceride level between 200 and 499 mg per deciliter, and an HDL cholesterol level of 40 mg per deciliter or less were randomly assigned to receive 0.2-mg tablets of pemafibrate twice daily or placebo. In the PROMINENT trial, two cohorts . . .
科研通智能强力驱动
Strongly Powered by AbleSci AI